Advancement in medical treatment of patients with influenza and other ARVI

Abstract

Based on the examination of 180 patients with influenza and other ARVI established following. Addition of base therapy of such patients of altabor in a dose 2 tablets for 20 mg 4 times daily during 7 days was accompanied by a significant advantage compared with only basic therapy on several grounds: the greater the number of patients advancing recovery up to 7 days, most regressed cough, relatively less there were complications.
After 7 days of altabor application WBC and relative content of stab neutrophils and lymphocytes is normalized, increased leukocyte index of intoxication, approaching normal values, significantly increases the index shift of leukocytes, significantly reduced lymphocytic index closer to normal.
This treatment also provides reduction of immunological disorders detected before treatment. Thus, the statistical weight increases the number of white blood cells and normal lymphocytes, maintained at normal levels of IgA and lysozyme concentrations and normal or even increased levels of IFN-α and IFN-γ.
On background application of altabor in a therapeutic dose by-reactions arose up all in 3 (3,33%) from 90 patients, which was classified as credible, supposed and not serious.